tiprankstipranks
Trending News
More News >
Abivax SA (FR:ABVX)
:ABVX
Advertisement

Abivax SA (ABVX) AI Stock Analysis

Compare
24 Followers

Top Page

FR:ABVX

Abivax SA

(LSE:ABVX)

Rating:58Neutral
Price Target:
€67.00
▼(-12.42% Downside)
Abivax SA's overall stock score of 58 reflects its strong revenue growth and liquidity position offset by significant profitability challenges and a highly leveraged balance sheet. Technical indicators suggest robust price momentum, though the valuation is constrained by negative earnings.

Abivax SA (ABVX) vs. iShares MSCI France ETF (EWQ)

Abivax SA Business Overview & Revenue Model

Company DescriptionABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
How the Company Makes MoneyAbivax generates revenue primarily through partnerships and collaborations with pharmaceutical companies and research institutions. The company may receive milestone payments and royalties from its partners upon achieving specific developmental or commercial targets for its drug candidates. Additionally, funding through grants and public offerings can contribute to its financial resources. As a clinical-stage company, its current revenue streams are limited, and it relies on external funding and partnerships to support its research and development activities.

Abivax SA Financial Statement Overview

Summary
Abivax SA shows significant revenue growth but struggles with profitability, having negative net income and operating cash flow. The balance sheet is highly leveraged, though the company maintains a strong cash position which supports liquidity.
Income Statement
35
Negative
Abivax SA has shown significant revenue growth from 2023 to 2024, but remains unprofitable with negative EBIT and net income. The company's gross profit margin is favorable, indicating effective cost control relative to revenue. However, the negative net profit margin highlights ongoing challenges in achieving profitability.
Balance Sheet
50
Neutral
The financial structure of Abivax SA is marked by a relatively high debt-to-equity ratio, indicating significant leverage which could pose risks. The equity ratio is low, reflecting limited shareholder equity relative to total assets. However, the company maintains a strong cash position, supporting liquidity.
Cash Flow
40
Negative
Abivax SA's cash flow from operations is negative, pointing to challenges in generating cash from its core activities. Free cash flow is also negative, but the company has maintained its liquidity through financing activities. The operating cash flow to net income ratio is unfavorable, indicating reliance on external funding.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue10.79M4.62M4.58M37.00K14.00K
Gross Profit10.79M4.49M4.51M-119.00K-52.00K
EBITDA-167.68M-133.21M-53.31M-42.20M-37.74M
Net Income-176.24M-147.74M-60.74M-42.45M-37.55M
Balance Sheet
Total Assets205.23M327.06M73.35M110.36M71.30M
Cash, Cash Equivalents and Short-Term Investments144.22M260.99M26.95M60.70M29.30M
Total Debt97.36M55.46M39.16M53.45M33.98M
Total Liabilities164.64M131.05M71.47M81.59M66.63M
Stockholders Equity40.58M196.01M7.19M25.93M17.90M
Cash Flow
Free Cash Flow-154.72M-97.39M-69.55M-47.30M-30.72M
Operating Cash Flow-154.07M-97.13M-65.58M-45.66M-29.82M
Investing Cash Flow15.76M-8.10M-3.73M-1.46M-575.00K
Financing Cash Flow28.21M335.29M32.21M82.68M49.93M

Abivax SA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price76.50
Price Trends
50DMA
44.13
Positive
100DMA
24.98
Positive
200DMA
15.78
Positive
Market Momentum
MACD
7.31
Positive
RSI
84.99
Negative
STOCH
93.63
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABVX, the sentiment is Positive. The current price of 76.5 is above the 20-day moving average (MA) of 65.10, above the 50-day MA of 44.13, and above the 200-day MA of 15.78, indicating a bullish trend. The MACD of 7.31 indicates Positive momentum. The RSI at 84.99 is Negative, neither overbought nor oversold. The STOCH value of 93.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ABVX.

Abivax SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
€5.50B-148.98%18.52%
51
Neutral
$7.92B-0.43-41.67%2.21%22.29%-1.85%
$198.63M112.392.17%
$197.93M-160.99%
€214.93M-152.03%
€620.53M
€649.83M-38.01%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:ABVX
Abivax SA
76.50
65.62
603.13%
GNFTF
Genfit
3.72
-0.47
-11.22%
IPHYF
Innate Pharma SA
2.06
-0.32
-13.45%
GB:0QAJ
DBV Technologies
1.50
0.73
94.81%
GB:0RNK
Inventiva
4.47
2.19
96.05%
GB:0OB3
Valneva
3.71
0.63
20.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 01, 2025